Market Mover: Neurometrix (NURO) Falls at Midday August 4

Equities Staff  |

Shares of Neurometrix Inc. (NASDAQ: NURO) lost 7.81% Thursday.

As of 11:57:43 est, Neurometrix is currently sitting at $3.75 and has moved $0.32 per share in trading so far.

Neurometrix has moved 12.64% over the last 30 days and has moved YTD 18.33% based on the prior day’s close.

The company is set to release earnings on 2022-10-20.

For technical charts, analysis, and more on Neurometrix visit the company profile.

About Neurometrix Inc.

NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® is a wearable neurostimulation device indicated for symptomatic relief of chronic pain that is available over-the-counter.

To get more information on Neurometrix Inc. and to follow the company's latest updates, you can visit the company's profile page here: Neurometrix Inc.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content